All In Biotech

Drug Trial Radar · NCT03818035

A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies With Guselkumab in Patients With Moderate-to-Severe Plaque-Type Psoriasis

Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 880 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

880

Actual

Start

Feb 8, 2019

Primary completion

Mar 7, 2022

Study completion Jan 7, 2025

Sponsor

Lead sponsor
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged treatment intervals of 16 weeks (guselkumab 100 mg every 16 weeks).

Conditions

  • Psoriasis

Interventions

  • GuselkumabDrug

    Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.

  • Placebo InjectionDrug

    Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Group 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 68Time frame: Week 68

Locations

90 sites in 2 countries. Site status is shown where the registry gives one.

  • Hopital Prive d'Antony

    Antony, France

  • Centre Hospitalier d'Auxerre

    Auxerre, France

  • Polyclinique Reims Bezanne - De Courlancy

    Bezanne, France

  • Centre Hospitalier Le Mans

    Le Mans, France

  • Hôpital Edouard Herriot

    Lyon, France

  • Le Bateau Blanc

    Martigues, France

  • CHU Nantes

    Nantes, France

  • CHU de Nice Hopital de l Archet

    Nice, France

  • CHU Rouen

    Rouen, France

  • HIA se Sainte-Anne - Toulon

    Toulon, France

  • CHU Toulouse

    Toulouse, France

  • Universitätsklinikum Aachen

    Aachen, Germany

  • DermaManagement Augsburg GmbH

    Augsburg, Germany

  • Klinikum Augsburg

    Augsburg, Germany

  • Fachklinik Bad Bentheim

    Bad Bentheim, Germany

  • Hautmedizin Bad Soden

    Bad Soden am Taunus, Germany

  • Charite CCM, Dermatologie

    Berlin, Germany

  • Vivantes Klinikum Im Friedrichshain

    Berlin, Germany

  • Rothhaar Studien GmbH

    Berlin, Germany

  • ISA - Interdisciplinary Study Association GmbH

    Berlin, Germany

  • Hautarztpraxis

    Berlin, Germany

  • Hautarztpraxis Dr.Wildfeuer

    Berlin, Germany

  • Hautarztpraxis

    Berlin, Germany

  • Praxis 'Haut Pur'

    Berlin, Germany

  • Klinikum Bielefeld Rosenhoehe

    Bielefeld, Germany

  • Katholisches Klinikum Bochum gGmbH

    Bochum, Germany

  • Niesmann & Othlinghaus GbR

    Bochum, Germany

  • MVZ Dermatologisches Zentrum Bonn GmbH

    Bonn, Germany

  • Universitatsklinikum Bonn

    Bonn, Germany

  • Hautarztpraxis

    Borna, Germany

  • Hautarztpraxis

    Bramsche, Germany

  • Derma Nord

    Bremen, Germany

  • Universitaetsklinikum Koeln

    Cologne, Germany

  • Klinikum Darmstadt GmbH - Hautklinik

    Darmstadt, Germany

  • Rosenpark Research GmbH

    Darmstadt, Germany

  • Klinische Forschung Dresden GmbH

    Dresden, Germany

  • Praxis für Dermatologie und Venerologie

    Dresden, Germany

  • University Hospital Dresden

    Dresden, Germany

  • Pro Derma

    Dülmen, Germany

  • Privatpraxis Dr. Hilton & Partner

    Düsseldorf, Germany

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.